HAMP and obesity disorder: Treatment with dapagliflozin has been shown to suppress hepcidin levels.52 Given that SGLT2 inhibition has been shown to decrease adipose tissue inflammation in a murine model of obesity,53 this point also raises the intriguing possibility that SGLT2 inhibition might decrease hepcidin levels via an anti-inflammatory effect, subsequently improving anemia associated with HFrEF.